Drug interactions and the cytochrome P450 system. The role of cytochrome P450 2C19

D. A. Flockhart

Research output: Contribution to journalArticle

79 Citations (Scopus)

Abstract

On the basis of the data currently available, the wild type cytochrome P450 2C19 (CYP2C19) gene appears to be absent in 2 to 6% of Caucasian populations and up to 20% of Asian populations. A poor metaboliser phenotype therefore results. The CYP2C19 phenotype can be determined clinically by use of either mephenytoin or omeprazole as the probe. Since both drugs are metabolised primarily by CYP2C19 in human liver microsomes, they are both useful, competitive inhibitors of CYP2C19 activity available to researchers working in vitro. The 2 known mutant alleles of CYP2C19 do not result in the expression of active enzyme and can be tested by using small samples of whole blood. No rapid mutants have been identified. A number of drugs have been shown to inhibit CYP2C19 in vivo, including fluvoxamine and fluoxetine. Important drug interactions may result from inhibition of hepatic CYP2C19 activity in extensive metabolisers or from the interaction of CYP2C19 substrates with other pathways in poor metabolisers.

Original languageEnglish (US)
Pages (from-to)45-52
Number of pages8
JournalClinical Pharmacokinetics
Volume29
Issue number4 SUPPL. 1
StatePublished - 1995
Externally publishedYes

Fingerprint

Drug Interactions
Cytochrome P-450 Enzyme System
Mephenytoin
Fluvoxamine
Phenotype
Omeprazole
Fluoxetine
Liver Microsomes
Pharmaceutical Preparations
Population
Alleles
Research Personnel
Liver
Enzymes
Genes

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Drug interactions and the cytochrome P450 system. The role of cytochrome P450 2C19. / Flockhart, D. A.

In: Clinical Pharmacokinetics, Vol. 29, No. 4 SUPPL. 1, 1995, p. 45-52.

Research output: Contribution to journalArticle

@article{7161d0e22114497ca50b04af3fbe3533,
title = "Drug interactions and the cytochrome P450 system. The role of cytochrome P450 2C19",
abstract = "On the basis of the data currently available, the wild type cytochrome P450 2C19 (CYP2C19) gene appears to be absent in 2 to 6{\%} of Caucasian populations and up to 20{\%} of Asian populations. A poor metaboliser phenotype therefore results. The CYP2C19 phenotype can be determined clinically by use of either mephenytoin or omeprazole as the probe. Since both drugs are metabolised primarily by CYP2C19 in human liver microsomes, they are both useful, competitive inhibitors of CYP2C19 activity available to researchers working in vitro. The 2 known mutant alleles of CYP2C19 do not result in the expression of active enzyme and can be tested by using small samples of whole blood. No rapid mutants have been identified. A number of drugs have been shown to inhibit CYP2C19 in vivo, including fluvoxamine and fluoxetine. Important drug interactions may result from inhibition of hepatic CYP2C19 activity in extensive metabolisers or from the interaction of CYP2C19 substrates with other pathways in poor metabolisers.",
author = "Flockhart, {D. A.}",
year = "1995",
language = "English (US)",
volume = "29",
pages = "45--52",
journal = "Clinical Pharmacokinetics",
issn = "0312-5963",
publisher = "Adis International Ltd",
number = "4 SUPPL. 1",

}

TY - JOUR

T1 - Drug interactions and the cytochrome P450 system. The role of cytochrome P450 2C19

AU - Flockhart, D. A.

PY - 1995

Y1 - 1995

N2 - On the basis of the data currently available, the wild type cytochrome P450 2C19 (CYP2C19) gene appears to be absent in 2 to 6% of Caucasian populations and up to 20% of Asian populations. A poor metaboliser phenotype therefore results. The CYP2C19 phenotype can be determined clinically by use of either mephenytoin or omeprazole as the probe. Since both drugs are metabolised primarily by CYP2C19 in human liver microsomes, they are both useful, competitive inhibitors of CYP2C19 activity available to researchers working in vitro. The 2 known mutant alleles of CYP2C19 do not result in the expression of active enzyme and can be tested by using small samples of whole blood. No rapid mutants have been identified. A number of drugs have been shown to inhibit CYP2C19 in vivo, including fluvoxamine and fluoxetine. Important drug interactions may result from inhibition of hepatic CYP2C19 activity in extensive metabolisers or from the interaction of CYP2C19 substrates with other pathways in poor metabolisers.

AB - On the basis of the data currently available, the wild type cytochrome P450 2C19 (CYP2C19) gene appears to be absent in 2 to 6% of Caucasian populations and up to 20% of Asian populations. A poor metaboliser phenotype therefore results. The CYP2C19 phenotype can be determined clinically by use of either mephenytoin or omeprazole as the probe. Since both drugs are metabolised primarily by CYP2C19 in human liver microsomes, they are both useful, competitive inhibitors of CYP2C19 activity available to researchers working in vitro. The 2 known mutant alleles of CYP2C19 do not result in the expression of active enzyme and can be tested by using small samples of whole blood. No rapid mutants have been identified. A number of drugs have been shown to inhibit CYP2C19 in vivo, including fluvoxamine and fluoxetine. Important drug interactions may result from inhibition of hepatic CYP2C19 activity in extensive metabolisers or from the interaction of CYP2C19 substrates with other pathways in poor metabolisers.

UR - http://www.scopus.com/inward/record.url?scp=0029085322&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029085322&partnerID=8YFLogxK

M3 - Article

VL - 29

SP - 45

EP - 52

JO - Clinical Pharmacokinetics

JF - Clinical Pharmacokinetics

SN - 0312-5963

IS - 4 SUPPL. 1

ER -